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Medicinal plants as a rich pool for developing novel small molecule therapeutic medicine
have been used for thousands of years. Carnosol as a bioactive diterpene compound
originated from Rosmarinus officinalis (Rosemary) and Salvia officinalis, herbs extensively
applied in traditional medicine for the treatment of multiple autoimmune diseases (1). In
this study, we investigated the therapeutic effects and molecule mechanism of carnosol in experimental autoimmune encephalomyelitis (EAE), an animal model of multiple
sclerosis (MS). Carnosol treatment significantly alleviated clinical development in the
myelin oligodendrocyte glycoprotein (MOG35–55) peptide-induced EAE model, markedly
decreased inflammatory cell infiltration into the central nervous system and reduced
demyelination. Further, carnosol inhibited Th17 cell differentiation and signal transducer
and activator of transcription 3 phosphorylation, and blocked transcription factor NF-κB
nuclear translocation. In the passive-EAE model, carnosol treatment also significantly
prevented Th17 cell pathogenicity. Moreover, carnosol exerted its therapeutic effects
in the chronic stage of EAE, and, remarkably, switched the phenotypes of infiltrated
macrophage/microglia. Taken together, our results show that carnosol has enormous
potential for development as a therapeutic agent for autoimmune diseases such as MS.
Keywords: Carnosol, multiple sclerosis, experimental autoimmune encephalomyelitis, Th17 cell, macrophage/
microglia

INTRODUCTION
Multiple sclerosis (MS) and its animal model, experimental autoimmune encephalomyelitis (EAE),
are chronic immune-mediated demyelinating diseases of the central nervous system (CNS), characterized by infiltrated inflammatory cells, demyelination, and damage to neurons (2). Although
the underlying mechanism of MS has not been well defined, a growing body of evidence supports
its being an autoimmune disease (3). While Th1 cells have been considered pathogenic for MS/
EAE, Th17 cells, a subpopulation of pro-inflammatory T helper cells defined by their secretion of
IL-17 (4), have recently emerged as an important player in inflammatory and autoimmune diseases via the secretion of pro-inflammatory cytokines, such as IL-17A, IL-17F, GM-CSF, and IL-22
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(5, 6). Polarization of Th17 populations and the related cytokine
production are directly regulated by RORγt (7), and the signals
that cause Th17 cells to differentiate actually inhibit regulatory
T cell (Treg) differentiation (8). Therefore, targeted inhibition of
RORγt transcription or a Th17 differentiation-related signaling
pathway such as NF-κB and signal transducer and activator of
transcription 3 (STAT3) represents an encouraging therapeutic
strategy in treatment of Th17-related diseases (4, 9, 10).
Current MS therapies either have limited efficacy or important safety issues (11, 12). A great deal of research effort has
gone into developing novel therapies that specifically target
Th17 cells, while sparing other immune cells. Recently, several
new anti-inflammatory or immunomodulatory drugs derived
from medicinal plants have been explored and are considered
to have great potential for treatment of autoimmune diseases
(4, 13–15). These natural compounds represent a rich source for
the identification of effective and safe candidate medicines with
innovative targets and/or mechanisms of action in the therapy of
MS and other autoimmune diseases.
Rosmarinus officinalis (rosemary) and Salvia officinalis are
common household plants that grow all over the world and have
been used as medicinal herbs due to their powerful antioxidant
and anti-inflammatory effects (16, 17). Carnosol, a major diterpene present in R. officinalis (rosemary) and S. officinalis, has been
reported to possess strong antioxidant, anti-tumor, anti-viral,
and especially anti-inflammatory properties (18–20). Carnosol
treatment also induced T-cell leukemia/lymphoma apoptosis
and decreased IL-6 and TNF-α levels in serum (21, 22). These
studies indicate that carnosol may be effective in the treatment
of autoimmune diseases; however, this possibility has not been
tested. To elucidate this question, in the present work, we studied
the potential therapeutic anti-inflammatory abilities of carnosol
on actively induced and adoptively transferred EAE models and
the mechanism of its action.

(200 ng/mouse) was injected intraperitoneally (i.p.) on days 0
and 2. Clinical EAE was assessed by daily scoring using a 0–5
scale as described previously (24). Carnosol was obtained from
Sigma-Aldrich (St. Louis, MO, USA) and was injected (50 mg/kg/
day) i.p. daily starting at day 0 p.i.

Histological and Immunofluorescence
Staining

Mice were euthanized at different time points after drug administration, and transcardially perfused with PBS. Tissues (brains and
spinal cords) were collected for pathological assessment. Spinal
cords were fixed with 4% paraformaldehyde overnight, cut into
5 µm sections and stained with H&E (hematoxylin and eosin) for
inflammation and Luxol fast blue (LFB) for demyelination. Slides
were examined and assessed following a previously described
method (23).
For immunofluorescence, brain and spinal cord were
cryopreserved in OCT compound (Tissue-Tek, Sakura Finetek,
Japan) for frozen sections and cut into 12 µm sections (25).
Immunofluorescence staining was performed using general
methods and the appropriate dilutions of primary antibodies
were applied. Immunofluorescence controls were routinely
performed with incubations in which primary antibodies were
omitted. Images were acquired by Nikon Eclipse E600 fluorescent
microscopy (Nikon, Melville, NY, USA). For quantification of
CD45+, MOG+, MBP+, iNOS+, Arg1+, and CD68+, 10 areas of the
sections were selected and analyzed as previously described (23).

Cytokine Measurement by ELISA

Splenocytes from EAE mice were prepared and cultured in
triplicates in RPMI 1640 supplemented with 10% fetal bovine
serum (Thermo Fisher Scientific) and stimulated with 25 µg/ml
MOG35–55 for 3 days. Cell-free supernatants were harvested and
analyzed for IFN-γ, IL-17, GM-CSF, IL-5, and IL-10 by ELISA
Kits (R&D Systems).

MATERIALS AND METHODS

Mononuclear Cell (MNC) Preparation

EAE Induction and Treatment

Splenocytes of EAE mice were mechanically pushing spleen
tissue through a 70 µm strainer (Falcon, Tewksbury, MA, USA)
and treated with red blood cell (RBC) lysis buffer (Biolegend, San
Diego, CA, USA) for 60 s. Collected cells were flushed with precold PBS before stimulation. To collect MNC from CNS tissue,
brain and spinal cords were administered with Liberase (Roche,
Nutley, NJ, USA) for half hour and dissociated through a 70 µm
strainer and flushed with pre-cold PBS. Cells were then separated
by 70/30% percoll (Sigma-Aldrich) gradient method following
previously described (26).

Female C57BL/6 mice (purchased from the Fourth Military
University (Xi’an, China)) were used at the age of 8 weeks.
All animal experiments were performed with the approval of
the Institutional Animal Care and Use Committee of Shaanxi
Normal University and according to the approved institutional
guidelines and regulations. For acute and chronic EAE, a previously described method was followed (23). Briefly, mice were
subcutaneously injected with 200 µg of myelin oligodendrocyte
glycoprotein (MOG) peptide 35–55 (Genescript, Piscataway, NJ,
USA) in 200 µl of emulsified complete Freund’s adjuvant with
5 mg/ml Mycobacterium tuberculosis H37Ra (Difco, Lawrence,
KS, USA). For adoptive transfer EAE, mice were sacrificed
10 days after MOG35–55 immunization, and splenocytes and
draining lymph nodes were provided as previously described
(4). Cells were cultured for 3 days in the presence of 25 µg/ml
MOG35–55, 10 ng/ml rmIL-23, and 2 ng/ml rmIL-2 (R&D Systems,
Minneapolis, MN, USA) at 1 × 107 cell/ml. CD4+ T cells were
purified by CD4+ T cell isolation kit and 4 × 106 cells per mouse
were transferred via intravenous (i.v.) injection. Pertussis toxin
Frontiers in Immunology | www.frontiersin.org

In Vitro T Cell Polarization

Polarization of Th1, Th17, and Treg cells was induced in vitro
following a previously described method (4). Naive 8-week-old
female C57BL/6 mice were sacrificed and spleen tissue was dissociated to single cell. Mouse CD4 microbeads (Miltenyi Biotech
Inc.) were used to purify the CD4+ T cells. Then, cells were
cultured for 3 days under their respective polarizing conditions
(27). Cells were stimulated for 3 days and examined on FACSAria
(BD Biosciences).
2
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Flow Cytometry Analysis

signs daily on a 0–5 scale. The PBS-treated group of mice showed
the first signs of EAE on day 10 p.i., while the carnosol-treated
mice did so on day 12 p.i. Further, daily carnosol administration
apparently led to decreased disease severity compared to the PBStreated control group (p < 0.01; Figure 1A).
We then evaluated pathological changes by histologic analyses
in lumbar spinal cords to examine CNS inflammatory infiltration
and demyelination at day 30 p.i. As shown in Figure 1B, massive
inflammatory infiltration and demyelination was observed in the
spinal cord of PBS-treated EAE mice; by contrast, the carnosoltreated group displayed mild to moderate signs (p < 0.0001;
Figures 1B–D). These results indicated that carnosol had a
significantly suppressive effect in acute EAE.

For cell surface staining, fluorochrome-conjugated Abs to CD4
(BD Biosciences, San Jose, CA, USA) or isotype control Abs were
added to cells for 30 min. For all intracellular staining, CNSinfiltrating MNCs or splenocytes were stimulated for 5 h with
phorbol 12-myristate 13 acetate (50 ng/ml), ionomycin (500 ng/
ml) (Sigma-Aldrich), and GolgiPlug (BD Biosciences). The staining procedure was performed following a previously described
protocol (4). Data were analyzed with FlowJo software (Treestar,
Ashland, OR, USA).

Quantitative PCR

Total RNA from T cells or microglia cells was extracted by
RNeasy Plus Mini Kit (QIAGEN, Valencia, CA, USA). cDNA
was synthesized with QuantiTect Reverse Transcription Kit
(QIAGEN). Quantitative PCR was performed in ABI Prism 7500
Sequence Detection System (Applied Biosystems, Foster City,
CA, USA) using QuantiFast SYBR Green PCR Kit (QIAGEN).
All experiments involving mRNA levels were normalized to
glyceraldehyde 3-phosphate dehydrogenase and primers that
were based on published cDNA sequences are listed in Table S2
in Supplementary Material.

Western Blot

T cells were activated on 24-well plate under Th17 differentiation
condition w/o carnosol 10 µg/ml for 18 h and were then collected.
Cells were lysed by cell lysis buffer (Cell Signaling Technology,
Danvers, MA, USA) supplemented with 1 mM phenylmethylsulfonyl fluoride (Cell Signaling Technology). All samples containing 15 µg total proteins were separated by 10% SDS-PAGE
and transferred to polyvinylidene difluoride membrane (Pierce
Chemical, Rockford, IL, USA). Membranes were blocked with
5% (w/v) nonfat dry milk powder in Tris-buffered saline (TBS)
for 2 h at room temperature. This was followed by incubation
at 4°C overnight with primary antibodies. Afterward, the membrane was washed three times in TBS plus Tween and incubated
with the corresponding secondary antibodies (Cell Signaling
Technology). The protein band was detected using Pierce ECL
Western Blotting Substrate (Thermo Fisher Scientific, Waltham,
MA, USA).

Statistical Analysis

Data were analyzed using GraphPad Prism 6 software (GraphPad,
La Jolla, CA, USA), and are presented as the mean ± SD.
Significant differences in comparing multiple groups, data were
analyzed by Tukey’s multiple comparisons test. All other statistical comparisons were done using nonparametric statistical
tests. Differences with p values of less than 0.05 were considered
significant.

Figure 1 | Carnosol ameliorated clinical severity of experimental
autoimmune encephalomyelitis (EAE). C57BL/6 mice were injected i.p.
with PBS or carnosol (50 mg/kg) daily starting on the day of EAE
induction, and scored daily following a 0–5 scale (A). (B) Mice were
sacrificed at day 30 p.i. and spinal cords were harvested. Sections at
lumbar level (L3) were analyzed by H&E and Luxol fast blue (LFB) (scale
bar = 1 mm), and pathology scores of inflammation (C) and percentage of
demyelination area (D) were evaluated. Data are mean ± SD (n = 5 each
group). **p < 0.01 and ****p < 0.0001, determined by two-way ANOVA
(A), or nonparametric test (C,D). One representative of three independent
experiments is shown.

RESULTS
Carnosol Treatment Remarkably Alleviated
Acute Clinical EAE

We first tested whether carnosol was effective in ameliorating
the clinical severity of MOG-induced EAE by scoring disease

Frontiers in Immunology | www.frontiersin.org
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Figure 2 | Carnosol treatment suppressed inflammatory infiltration in the central nervous system (CNS). Mice were treated with PBS or carnosol at the day of
experimental autoimmune encephalomyelitis induction and sacrificed at day 30 p.i. (A) Spinal cords were subjected to immunostaining analysis. (A) Representative
sections of thoracic spinal cord from PBS- and carnosol-treated mice were stained with CD45 and MOG (scale bar = 100 μm), and the number of CD45+ cells
(B) and the intensity of MOG staining (C) were statistically analyzed. (D) Spinal cords and brains were harvested and mononuclear cells (MNCs) isolated (n = 10
each group). Total MNC numbers in CNS were counted under light microscopy. (E) The percentage of CD4+ T cells was measured by flow cytometry. (F) Absolute
numbers of infiltrated CD4+ T were calculated by multiplying the percentages of these cells with total numbers of MNCs in each spinal cord and brain tissue. (G–J)
Frequencies of IFN-γ+, IL-17+, GM-CSF+, and Foxp3+ cells among CD4+ cells were assessed by flow cytometry, and (K) the percentages of these cells in total CD4+
cell numbers in each CNS are shown. Symbols represent mean ± SD (n = 5 each group). **p < 0.01 and ***p < 0.001. Student’s t-test. One representative of three
independent experiments is shown.
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Carnosol Suppressed CNS Inflammation
and Modulated Peripheral Immune
Response in Acute EAE

group, which was consistent with the findings in the CNS infiltrated cells, as shown in Figures 2G–K. Overall, our data show
that carnosol specifically inhibited the cytokine production of
pathogenic Th17 cells.

To evaluate the therapeutic effects of carnosol on CNS pathology,
spinal cords were obtained from carnosol- and PBS-treated EAE
mice. Analysis of spinal cord tissue sections showed abundant
CD45+ inflammatory cells in the lesion area in the PBS-treated
group, while these cells could barely be detected in the spinal cord
tissue sections of carnosol-treated mice (p < 0.01; Figures 2A,B).
Correspondingly, there was significantly reduced demyelination
(MOG− area) in carnosol-treated mice compared with the PBStreated group (p < 0.01; Figures 2A,C). These results were consistent with the HE and LFB staining, indicating that carnosol inhibited
inflammatory cell infiltration and demyelination in the CNS.
To further evaluate the effects of carnosol on the infiltrated
inflammatory T cells into the CNS, MNCs were separated from
the CNS and analyzed by flow cytometry. The total number of
MNCs was 703.8 ± 119.0 × 104 per mouse in the PBS-treated
group vs. 382.6 ± 93.59 × 104 in the carnosol-treated group
(p < 0.01; Figure 2D). In addition, carnosol treatment significantly
decreased the percentage and absolute numbers of CD4+ cells in
the CNS compared to the PBS-treated control (Figures 2E,F).
Furthermore, while the percentages of CD4+IFN-γ+ (Th1) and
CD4+Foxp3+ (Treg) cells remained unchanged, percentages of
CD4+IL17+, CD4+GM-CSF+, and IFN-γ+IL-17+ cells decreased
dramatically after carnosol treatment (p < 0.001; Figures 2G–K;
Figure S1 in Supplementary Material). These results indicate
that carnosol may play a significant role in the inhibition of CNS
inflammatory infiltration, especially in the pathogenic Th17 cell
population.
To study the autoantigen-induced cytokine production in the
peripheral immune system of carnosol-treated mice, spleen cells
were collected at day 30 p.i. and pulsed with MOG35–55. As shown
in Figure 3, the protein levels of IL-17 and GM-CSF in cell culture
supernatants were significantly decreased in the carnosol-treated

Carnosol Mediated Its Immunomodulation
Function by Inhibiting Th17 Cell
Differentiation

To clarify the mechanism underlying the effects of carnosol on
CD4+ T cell subsets, we defined its function in Th1, Th17, and
Treg cell polarization in vitro. Under Th17-differentiation condition, about 25% of CD4+ cells were IL-17+ in the PBS group,
while carnosol treatment at a dose of 10 µM significantly reduced
Th17-polarized (IL-17-producing) CD4+ T cells (25.06 ± 2.13 vs.
4.47 ± 0.52%, p < 0.01) (Figures 4A,D). In addition, carnosol
treatment suppressed Th17 differentiation in a dose-dependent
manner. We then investigated the effects of carnosol on Th1 and
Treg cell differentiation. In contrast to the findings for Th17 cells,
IFN-γ or Foxp3 expression under Th1 or Treg polarizing condition was not significantly affected under carnosol treatment
(Figures 4B–D). Taken together, these data suggest that carnosol
selectively inhibits Th17 polarization.

Carnosol Suppressed STAT3 and NF-κB
Phosphorylation, Which Is Required for
Th17 Differentiation

Inflammatory cytokine production depends on early events in the
NF-κB signaling pathway (28). In order to study the mode of action
of carnosol in T cell differentiation, the phosphorylation status
of NF-κB was determined by Western blot. p65 phosphorylation
at Ser536 regulates its activation and nuclear translocation (29).
Results showed that carnosol suppressed cell response by a shift
of NF-κBp65 to the cell nucleus, which was demonstrated by the
proper shift in the ratio of phosphorylation NF-κB/total NF-κB
(Figures 4E,F). Further, the pro-inflammatory cytokines in the
downstream of NF-κB signal pathway, including IL-2 and TNF-α,
were also significantly decreased (Figure 4H).
Signal transducer and activator of transcription 3 activities
play an important role in the differentiation of Th17 cells. We
determined that the basal STAT3 phosphorylation level was
significantly decreased. The phosphorylation status at Tyr705
induced nuclear translocation and DNA binding, which
promotes IL-17 production (30). Our results showed that
carnosol treatment significantly suppressed STAT3 activation
(Figures 4E,G) and IL-17A and IL-17F production of Th17 cells
(Figure 4I) compared with the PBS-treated cells. In contrast,
similar expression levels were observed for NF-κB and STAT4
phosphorylation in carnosol- and PBS-treated Th1 cells (Figure
S2 in Supplementary Material). Together, these results indicate
that carnosol may specifically inhibit differentiation of Th17 cells
but not Th1 cells.

Figure 3 | Carnosol treatment decreased inflammation and cytokine
production. Mice were treated with PBS or carnosol at the day of
experimental autoimmune encephalomyelitis induction and sacrificed at day
30 p.i. as described in Figure 1A. Splenocytes were harvested and
stimulated with 25 µg/ml MOG35–55 for 3 days. Cytokine concentrations in
culture supernatants were measured by ELISA. n = 5. Symbols represent
mean ± SD (n = 5 each group). *p < 0.05 and **p < 0.01. Nonparametric
test. One representative of three independent experiments is shown.

Frontiers in Immunology | www.frontiersin.org

Carnosol Suppressed Pathogenicity
of Th17 Cells in Passive EAE

To assess the effect of carnosol on the encephalitogenicity of
Th17 cells, at day 10 p.i., MNCs were collected from lymph
5

August 2018 | Volume 9 | Article 1807

Li et al.

Carnosol Effectively Suppresses EAE

Figure 4 | Carnosol suppressed Th17 cell differentiation by blocking the function of NF-κB and signal transducer and activator of transcription 3 (STAT3).
(A) CD4+ cells were isolated from C57Bl/6 mice and cultured under the Th17 polarizing condition with different concentrations of carnosol for 3 days. Percentage of
Th17 cells was analyzed by intracellular staining of IL-17. (B,C) CD4+ cells were cultured under the Th1 and regulatory T cell (Treg) polarizing condition with carnosol
(10 µM) for 3 days. Percentages of Th1 and Treg cells were analyzed by intracellular staining of IFN-γ+ and Foxp3+, respectively. (D) Statistical analysis of
(A–C). (E) CD4+ T cells were cultured under Th17 polarizing condition and treated with 10 µM carnosol or PBS for 3 days. Cells were then analyzed for NF-κB
and STAT3 expression by Western blot. (F,G) Statistical analysis of (E). (H,I) Cells were harvested as described in (E) and subjected to RNA extraction and cDNA
production. Expression of pro-inflammation cytokines and IL-17 members (IL-17a and IL-17f) was determined by real-time PCR. Symbols represent mean ± SD
(n = 3 each group). *p < 0.05 and **p < 0.01. Student’s t-test. One representative of three independent experiments is shown.

nodes and spleen of IL-17A-IRES-GFP mice (C57BL/6 background), of which IL-17A-producing cells are GFP+ (The
Jackson Laboratory, Stock # 018472). Cells were cultured
under Th17-polarizing conditions with PBS or carnosol, and
stimulated by MOG35–55 (20 µg/ml). After 3 days of culture,

Frontiers in Immunology | www.frontiersin.org

CD4+ T cells were separated and i.v. injected into naïve C57BL/6
recipient mice. As shown in Figure 5A, carnosol-treated T cells
transferred significantly reduced clinical disease compared to
the PBS-treated group (p < 0.01). Mice were sacrificed after
20 days, and brain tissues from different groups were collected
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Carnosol Alleviated Clinical Disease When
Treatment Started at Chronic Stage of EAE

To further explore the therapeutic effects of carnosol, the chronic
EAE model was used in this study. Mice were treated starting
from day 25 p.i., when CNS demyelination and chronic tissue
damage were already established. While clinical scores in the
PBS-injected mice remained at 2.5–3.0, the disease was significantly alleviated in the carnosol-treated group after 10 days of
treatment (p < 0.01–0.001; Figure 6A). The results indicate that,
compared to the PBS-treated mice, carnosol showed potential
for blockade of demyelination and recovery from neurological
damage in the CNS, even when treatment was started after the
peak of disease.
Compared to acute EAE (e.g., day 25 p.i.), in chronic EAE (e.g.,
day 60 p.i.; Figures 6B,C), rare infiltration inflammation cells
were observed in the white matter of both PBS- and carnosoltreated mice, suggesting that neuroinflammation is no longer the
major pathogenesis in the chronic stage (23). On the other hand,
while PBS-treated EAE mice tended to have more severe demyelination, as shown by LFB and MBP staining, the demyelination
area was obviously decreased in carnosol-treated mice compared
to PBS-treated control mice. Increased MBP expression after carnosol treatment compared to that before treatment (day 25 p.i.)
suggests that carnosol might induce myelin protein regeneration
(Figures 6D–G).

Carnosol Promoted an M1/M2 Phenotype
Shift of Macrophage/Microglia

Given that microglia/infiltrating macrophages with the activated
type 1 phenotype (M1) have a significant role in CNS inflammation during EAE chronicity, whereas type 2 phenotype (M2) cells
are immunomodulatory and promyelinating (31, 32), we determined the effects of carnosol on these cells in the CNS tissues
of EAE mice that were euthanized after 60 days p.i. The number
of M1 microglia/infiltrating macrophages (iNOS+CD68+) was
decreased and an increase in M2 (Arg1+CD68+) phenotype was
observed in carnosol-treated mice compared to PBS-treated
control (Figures 7A–D). These results indicated that, at least
partially, carnosol inhibited demyelination and promoted myelin
recovery through inhibiting M1 microglia and switching them to
M2. To further confirm this hypothesis, primary microglia were
cultured with or without carnosol. Carnosol effectively inhibited
production of important mediators of microglia activation, e.g.,
TNF-α (Figure 7E), and expression levels of IL-1β, NOSII, and
TNF-α were also significantly decreased (Figure 7F). These
results indicated that carnosol inhibits the infiltration of M1
phenotype microglia and switches it to a promyelinating and
immunoregulatory M2 phenotype that promotes the process of
myelin regeneration (32).

Figure 5 | Carnosol decreased clinical severity in an adoptive transfer
model of experimental autoimmune encephalomyelitis (EAE). For adoptive
transfer EAE, single-cell suspensions were derived from spleen and lymph
nodes of IL-17A-IRES-GFP EAE mice at day 10 p.i. MOG (25 µg/ml) plus
IL-23 (10 ng/ml) and IL-2 (2 ng/ml) were added to cultures in the presence or
absence of carnosol (10 µM) for 3 days. 1 × 106 CD4 T cells were i.v. injected
to the recipient mice. (A) Mean clinical score of adoptive transfer EAE
(mean ± SD; n = 5 each group). **p < 0.01, Two-way ANOVA with Sidak
test. (B) Mice were sacrificed at day 20 after cell transfer, and brains were
subjected to immunostaining analysis of CD45+ and GFP+ cells (marker for
Th17 cells). Statistical analyses of total CD45+ cell numbers (C) and the
percentage of GFP+CD45+ cell (D) for staining in (B) are shown. Scale
bar = 100 µm. Symbols represent mean ± SD (n = 5 each group) **p < 0.01,
determined by two-way ANOVA (A), or nonparametric test (C,D). One
representative of two independent experiments is shown.

for immunohistochemistry. Results showed similar CD45+ cell
numbers in the tissue; however, in the CNS, the percentages of
GFP+/CD45+ cells in the carnosol-treated group were markedly reduced compared with the PBS-treated group (p < 0.01;
Figures 5B–D). These in vivo results further demonstrated a
suppression function of carnosol on the encephalitogenicity of
MOG-reactive Th17 cells.

Frontiers in Immunology | www.frontiersin.org

DISCUSSION
This work for the first time shows the beneficial effect of carnosol
on both acute and chronic stages of EAE. Carnosol significantly
decreased inflammatory infiltration into the CNS and the demyelination process, thus halting disease development. The role of
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Figure 6 | Carnosol treatment alleviated the clinical severity of chronic experimental autoimmune encephalomyelitis (EAE) mice. (A) Clinical scores of carnosol- and
PBS-treated mice at the chronic stage (treatment starting from day 25 p.i.) of EAE. Mice were sacrificed at day 60 p.i. (n = 5 each group), and spinal cords were
harvested and evaluated for cell infiltration by H&E staining (B), which was scored on a 0–3 scale (C), and for demyelination by Luxol fast blue (D). (E) Demyelination
area was measured using Image-Pro Plus software. (F) Sections of lumbar spinal cord from (A) were assayed for demyelination by MBP staining. (G) Quantitative
analysis of MBP expression. MBP intensity was measured in the lesion areas in the lumbar spinal cord using Image-Pro. Data represent mean ± SD (n = 10 each
group). Scale bar = 1 mm (B,D) or 100 µm (F). *p < 0.05, **p < 0.01, and ****p < 0.0001. Student’s t-test. One representative of three independent experiments is
shown.

carnosol in acute EAE is primarily due to its inhibitory effect
on Th17 cell differentiation, CNS infiltration, and encephalitogenicity, in which the STAT3 signaling pathway plays an important role. Further, the shift of microglia/infiltrated macrophage
phenotype from a pro-inflammatory (M1) to an immunoregulatory one (M2) may be an important mechanism underlying the
therapeutic effect of carnosol on the chronic stage of EAE.

Frontiers in Immunology | www.frontiersin.org

Carnosol, an ortho-diphenolic of abietane-type diterpenelactone, consists of an abietane carbon skeleton with hydroxyl
groups at positions C-11 and C-12 and a lactone moiety across
the B ring (18). Carnosol showed a broad range of physiological
benefits and bio-pharmacological effects, as well as exerted strong
anti-oxidant, anti-cancer, and neuroprotection effects (17, 20).
Furthermore, carnosol was reported to exert anti-inflammatory
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promising therapeutic drug for many incurable diseases, such
as neurodegeneration, cancer, and cardiovascular disorders (33,
34). However, the mechanism underlying these functions has not
been completely elucidated. Although it has already been shown
that carnosol stimulates the MAPKs signaling pathway and
down-regulates multiple transcription factors, including NF-κB
as well as pro-inflammation protein such as COX-2 level (35–37),
to our knowledge, this is the first study to show that carnosol
treatment leads to an inhibition in Th17 differentiation and that
it modulates microglial switch.
The major challenge for the clinical application of natural
compounds is determining their detailed molecular mechanism
(4). Indeed, the mechanism of carnosol’s action on T helper cell
differentiation in autoimmune disease remains largely unknown.
It has been suggested that carnosol suppresses inflammation by
targeting NF-κB signaling (37, 38), whose activation has been
found in MS brain lesions (39, 40) and peripheral blood (41), as
well as in the development of EAE (42, 43). Further, IL-17 plays a
key role in the pathogenesis of MS and EAE (9, 44). Specifically,
activated STAT3 is considered to be necessary for IL-17 production in mouse and human Th17 cells (45, 46). STAT3 controls
various genes that contribute to the Th17 population cells including the IL-17 locus itself (47), and binds to genes encoding transcription factors that are critical for Th17 polarization, including
Rorc, Irf4, and Batf (48). In our study, carnosol altered the level
of Th17 lineage-associated cytokine IL-17. This finding suggests
that carnosol inhibits polarization of T cells into Th17 cells, which
may be due to carnosol’s ability to diminish Th17-associated
cytokines by targeting the NF-κB signaling pathway. In response
to cytokines, STAT3 is phosphorylated by receptor-associated
Janus kinases and forms homo- or heterodimers that translocate
to the cell nucleus, where they act as transcription activators.
Here, we show that carnosol suppressed STAT3 phosphorylation
at the site of tyrosine 705, in response to the ligand IL-6. These
findings further identified the mechanism of carnosol through
suppressed NF-κB and STAT3 phosphorylation to block Th17
differentiation.
We have further identified the therapeutic effects of carnosol
on chronic stage of EAE, and investigated the involvement of
M1/M2 microglia shift as a potential mechanism of its action.
Persistent CNS inflammation, particularly the activation of
infiltrated macrophage/microglia, is recognized to be a crucial
mechanism underlying EAE chronicity (49). Pro-inflammatory
cytokines, including IL-1β, IL-6, and TNF-α, were secreted by
these inflammatory cells, which, together with the accumulation
of neurodegeneration inhibitors, form a hostile microenvironment against remyelination and neural repair (24). Therefore,
diminishing the inflammatory cytokines of the CNS niche and
promoting its change to a supportive environment for neural
repair and remyelination will be helpful for treatment. Here,
we showed that carnosol suppressed infiltrated macrophage/
microglia activation both in EAE mice in vivo and microglia
culture in vitro. A shift from M1 to M2 phenotype was observed
following carnosol treatment. Previous studies indicated that
carnosol reduced LPS-induced iNOS mRNA and protein
expression. Administration of carnosol resulted in a reduction
of nuclear factor-kappa B (NF-κB) subunit translocation and

Figure 7 | Carnosol promoted an M2 phenotype in macrophages/microglia.
Spinal cords of mice described in Figure 6 were stained for markers for M1
[iNOS; (A)] and M2 [Arg-1; (B)] on microglia/infiltrating macrophages (CD68+
cells). (C,D) Quantitative analysis of the percentages of double positive cells.
(E,F) Primary microglia were prepared from newborn B6 mice, stimulated
with LPS (100 ng/ml), and treated with carnosol at different concentrations
for 2 days and (E) supernatants were harvested for TNF-α production and
(F) cells were collected for expression levels of IL-1β, NOSII, and TNF-α by
real-time PCR. Glyceraldehyde 3-phosphate dehydrogenase was used as an
internal control. Scale bar = 100 µm. Data are shown as mean values ± SD
(n = 5 each group). ANOVA with Tukey’s multiple comparisons test was used.
*p < 0.05 and **p < 0.01. One representative of three independent
experiments is shown.

effects by reducing cytokine release (e.g., IL-1, IL-6) and iNOS
formation (18). Also, carnosol, as an anti-inflammatory
and anti-oxidant agent, has been considered as a potentially
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arise from dysfunctions in the immune system, these dysfunctions are extremely different. This phenomenon depends on the
complex in vivo process and is also due to the different molecule
target. Although it appears paradoxical that carnosol has antitumor capacity and the ability to suppress EAE, we hypothesize
that as a small molecule, carnosol may bind to various molecular
sites and induce different signaling pathways, an ability that may
be determined by different microenvironments.
In summary, the present study demonstrates that carnosol ameliorated clinical severity of acute and chronic EAE. We propose that
these effects are due to the inhibition of Th17 cell polarization and
a remarkably switched phenotype of infiltrated macrophages and
activated microglia. Taken together, our data indicate that carnosol
is a natural molecule that has potential for the treatment of MS, and
likely for autoimmune diseases in general.

NF-κB DNA binding activity in activated macrophages (50).
Further experimental data added proof that carnosol blockades
the IL-1β induced nuclear translocation of NF-κBp65, indicating that it mainly regulates through the NF-κB signaling (38).
These findings were consistent with our results and indicated that
carnosol could switch infiltrated macrophages/microglia from
M1 to M2 phenotype and may play an essential role in myelin
protein recovery.
One of the major mechanisms contributing to the chronic
progression in MS is loss of neurotrophic factor support for both
oligodendrocytes and neurons, resulting in persistent damage to
CNS tissue damage, i.e., demyelination, axonal degeneration, and
neuronal dysfunction (23). Exploring a novel medicine that both
targets neuroinflammation and promotes neuroregeneration
will, therefore, be of great value. Recently, Wang et al. showed the
protective role of carnosol against spinal cord injury (37). This
study led us to determine whether carnosol has a neuroprotective function in demyelinating disease. In the present study, we
observed that carnosol blocks demyelination by means of the M1/
M2 switch. However, no significant differences were observed in
OPC differentiation in vitro or in the cuprizone-induced demyelination model (data not shown). This finding may illustrate
that the underlying mechanism of carnosol-induced recovery
in EAE mice is not due to its direct effect on oligodendrocyte
differentiation/maturation, but rather an indirect effect through
immunomodulation and reduced CNS inflammation and the
M1/M2 switch, thus providing a supportive microenvironment
for neural cells.
Although we demonstrated the efficacy of carnosol treatment of EAE, the immunomodulatory mechanism is not clear.
We showed that carnosol could suppress IL-17 and GM-CSF
production of splenocytes, but we also found that carnosol exerts
its anti-inflammatory effect on microglia. Increasing evidence
shows that carnosol can cross the blood–brain barrier (BBB)
as a neuroprotective agent. We, therefore, provide compelling
evidence supporting an effective role of carnosol in inhibiting
Th17 cell differentiation in the periphery and modulating microglia phenotype by penetrating the BBB in the CNS.
In addition, a previous study showed that carnosol has antitumor capacity through prevention of Treg cell differentiation,
decreasing IL-4 and IL-10 production, and enhancing IFN-γ
secretion in tumor-associated lymphocyte populations (51).
Tumor Tregs are a highly heterogeneous population that arises
through disparate pathways and mediates immunologic effects
by various means including soluble cytokines (52). An explanation of the principal mechanism of their increase would include
a reaction to autoimmunity, tumor-specific factors, and control
of inflammation. Although autoimmune disease and cancer both
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